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Summary
In order to increase the cytotoxic activity of a Salmo-
nella strain carrying a salicylate-inducible expression
system that controls cytosine deaminase production,
we have modified both, the vector and the producer
bacterium. First, the translation rates of the expres-
sion module containing the Escherichia coli codA
gene cloned under the control of the Pm promoter
have been improved by using the T7 phage gene
10 ribosome binding site sequence and replacing
the original GUG start codon by AUG. Second, to
increase the time span in which cytosine deaminase
may be produced by the bacteria in the presence of
5-fluorocytosine, a 5-fluorouracyl resistant Salmo-
nella strain has been constructed by deleting its upp
gene sequence. This new Salmonella strain shows
increased cytosine deaminase activity and, after
infecting tumour cell cultures, increased cytotoxic
and bystander effects under standard induction con-
ditions. In addition, we have generated a purD muta-
tion in the producer strain to control its intracellular
proliferation by the presence of adenine and avoid the
intrinsic Salmonella cell death induction. This strat-
egy allows the analysis and comparison of the
cytotoxic effects of cytosine deaminase produced by
different Salmonella strains in tumour cell cultures.
Introduction
Bacteria can be easily adapted to synthesize proteins
with relevant biotechnological applications. Over the past
decade, many genera of bacteria have been explored
as cell factories for cancer therapy due to their ability
to specifically target tumours (Pawelek et al., 1997),
reviewed in (Forbes, 2010). Salmonella enterica serovar
Typhimurium (S. Typhimurium) is probably the intracellu-
lar pathogen that has been most extensively studied
as an anti-tumour vector due to its intrinsic properties.
These bacteria preferentially colonize and proliferate in
solid tumours at ratios greater than 1000/1 compared
with normal target organs, a behaviour that usually
results in tumour growth inhibition (Pawelek et al., 1997).
In addition, as a facultative anaerobe, Salmonella can
grow under aerobic and anaerobic conditions, which
allows bacteria to accumulate in large solid tumours and
invade metastases (Saltzman et al., 1996; Yam et al.,
2010).
Administration of attenuated Salmonella strains
expressing different anti-tumour agents has been
attempted in recent years with promising results in
tumour regression (Nemunaitis et al., 2003; Barnett
et al., 2005; Zhao et al., 2006; Royo et al., 2007; Jeong
et al., 2014). One of the therapeutic genes successfully
expressed in S. Typhimurium is the Escherichia coli
codA gene, encoding cytosine deaminase (CD). This
enzyme, present in fungi and bacteria but absent in
mammalian cells (Nishiyama et al., 1985), catalyses the
conversion of cytosine to uracil and ammonia (Koechlin
et al., 1966). Cytosine deaminase can also deaminate
the non-toxic cytosine analog, 5-fluorocytosine (5-FC) to
the toxic metabolite, 5-fluorouracil (5-FU) that is widely
used as a chemotherapeutic agent. This metabolite is
then converted by cellular enzymes into 5-FdUMP, which
inhibits DNA synthesis by blocking the activity of
thymidylate synthase, 5-FUTP and 5-FdUTP, which are
incorporated into RNA and DNA, respectively (Meyers
et al., 2003), thus leading to cell death (Polak and
Scholer, 1975; Damon et al., 1989). In addition, 5-FU
can freely diffuse across the cell membrane and
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produce its cytotoxic effects in neighbouring cells, a phe-
nomenon known as the bystander effect (Kuriyama
et al., 1998). Despite several co-administration studies
that have demonstrated conversion of 5-FC to 5-FU and
significant tumour growth reduction in animal models
(King et al., 2002; Nemunaitis et al., 2003; Royo et al.,
2007), its application in cancer patients has been limited
(Nemunaitis et al., 2003). Clinical data suggest that the
anti-tumour activity of 5-FU is directly related to both
the duration of drug exposure and its concentration in
the tumour (Nemunaitis et al., 2003). However, in order
to achieve a significant amount of active metabolites and
cell killing, the required dose of the apparently harmless
5-FC may be high enough to cause adverse effects
(reviewed in (Vermes et al., 2000)). This 5-FC toxicity
may be due, in part, to the conversion of 5-FC to 5-FU
by human intestinal microflora (Harris et al., 1986).
Increasing the anti-tumour activity and minimizing the
systemic toxicity would circumvent these problems, but
to achieve this, it is necessary to improve the selective
production of CD into the tumour. We have previously
validated an in vivo salicylate-inducible cascade ex-
pression system that allows the controlled cytosine
deaminase production. This system combines a set of
salicylate-regulated elements from Pseudomonas putida
that work in cascade, containing a regulatory module
(NahR and XylS2 transcription regulators coding
sequences) integrated in the chromosome of attenuated
S. Typhimurium aroA (SL7207 strain) and an expression
module, consisting in a codA gene cloned under the
control of the Pm promoter either in a plasmid or inte-
grated in the chromosome (Royo et al., 2007). In the
presence of salicylate, XylS2 promotes transcription
from Pm. In order to increase the CD production rates,
in this work we have improved the CD expression
module by engineering codA to be translated from the
T7 phage gene 10 ribosome binding site and changing
the original CD GUG start codon to AUG in new salicy-
late induced expression vectors (Medina et al., 2011).
Since the microbial uracil phosphoribosyltransferase,
encoded by upp, directly converts 5-FU to the metabolite
5-FUMP, from which the other toxic metabolites are pro-
duced, strains lacking this activity are more tolerant to
5-FU (Lundegaard and Jensen, 1999). To prevent killing
of the producing bacteria during accumulation of toxic
5-FU, thus increasing the time span in which Salmonella
produces CD, we have also constructed a 5-FU resistant
upp mutant. Finally, in order to assess the effects of CD
produced by improved strains and plasmids in tumour
cell cycle distribution and bystander activity in long-term
cell cultures, a purD mutation has been generated in the
producer strains to avoid cell death induced by intracel-
lular Salmonella proliferation (Leung and Finlay, 1991;
Mesa-Pereira et al., 2013).
Results and discussion
Construction of a Salmonella strain with high
salicylate-induced CD production rates
In order to increase the amount of CD produced keeping
standard induction conditions, we improved both the pro-
ducing Salmonella strain and the CD expression plasmid.
First, we transferred the new genome-integrated regula-
tory module previously developed in our laboratory
(Medina et al., 2011) to the SL7207 Salmonella strain,
thus generating the MPO375 strain (bacterial strains and
plasmid are listed in Supporting information Table S1,).
This regulatory module contains a constitutively ex-
pressed gfp gene to track Salmonella during the infection
process. Second, we modified this strain with the aim of
avoiding host cell death induced by Salmonella intracel-
lular proliferation (see below). To that end, we transduced
a ΔpurD mutation into MPO375 to get the strain MPO376.
In this way, intracellular proliferation can be controlled by
the amount of adenine in the culture medium (Leung and
Finlay, 1991; Mesa-Pereira et al., 2013). On the other
hand, we constructed new plasmids with higher CD
expression rates than pMPO16, the vector previously
used in our laboratory to express CD (Royo et al., 2007).
The E. coli codA sequence cloned in this plasmid has the
original GUG start codon and its own ribosome binding
site (from now on, CDGUG sequence). To increase CD
production, we changed the codA start codon to AUG and
cloned the resulting sequence into the high copy number
vector pMPO52 (Medina et al., 2011) to produce
pMPO88. In this vector, codA expression is under the
control of the Pm promoter and the T7 gene10 ribosome
binding site, a strong ribosome binding site that achieves
high translation levels (from now on, CD7AUG sequence).
We have previously reported that the salicylate-induced
expression levels of vectors based in pWSK29, a low
copy number vector that is stable through the whole Sal-
monella infection cycle without selection pressure, are
comparable to that of their corresponding high copy
number vectors (Medina et al., 2011). To generate ver-
sions of the CD expression modules in low copy number
plasmids, the engineered codA genes in pMPO88 and
pMPO16 were subcloned in the pWSK29 derived vector
pMPO20, thus generating plasmids pMPO90 and
pMPO1088 respectively.
To compare the amount of CD produced by the differ-
ent constructs, we analysed whole-cell protein extracts
from cultures of the strain MPO376 carrying the low
copy number vectors pMPO1088 (CDGUG) or pMPO90
(CD7AUG) by SDS-PAGE, in the presence or absence of
salicylate. As shown in Fig. 1A (lanes 4 and 6), the
pMPO90 vector produces more CD than pMPO1088
after salicylate induction. Afterwards, we determined the
CD activity from these cell lysates by analysing the
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conversion of 5-FC to the cytotoxic agent 5-FU. The
assays (Fig. 1B) revealed that, upon induction, the strain
harbouring the pMPO90 (CD7AUG) vector reached an
activity about 3.5-fold higher than the same strain
bearing pMPO1088 (CDGUG). Thus, these results dem-
onstrate that the new CD7AUG sequence produces higher
amounts of CD and therefore 5-FU than CDGUG using the
same Salmonella producer strain and concentrations of
salicylate and 5-FC.
Expression of CD with a 5-FU resistant
Salmonella strain
As shown before, the new vector pMPO90 (CD7AUG)
allows production of a larger amount of CD than the
former construct under salicylate induction. However,
since Salmonella is sensitive to 5-FU, the maximum rate
of synthesis of this cytotoxic metabolite could also be
limited by the maximum tolerated concentration and not
only by the amount of CD present in the bacterium. To test
this prediction, we first determined the growth of Salmo-
nella carrying different plasmids on plates containing
5-FC (Fig. 2). Cultures of strain MPO376 bearing either
the empty vector or one of the two CD-expressing
plasmids (pMPO1088 or pMPO90) were spotted on plates
in the presence or absence of salicylate and sup-
plemented with two different concentrations, 0.5 or 5 μM,
of 5-FC. Consistent with the results mentioned above, the
Salmonella strain carrying the plasmid pMPO90 presents
a more severe growth defect even at the low 5-FC con-
centration than the strain bearing pMPO1088 at the high
5-FC concentration, which correlates with its higher
expression of CD and, consequently, higher production
Fig. 1. Production of CD in low copy number expression vectors.
A. SDS-PAGE analysis of salicylate dependent overproduction of
cytosine deaminase. Whole extracts of Salmonella MPO376 (ΔpurD)
bearing pMPO54 (empty vector), pMPO1088 (CDGUG) or pMPO90
(CD7AUG) plasmids and Salmonella strain MPO378 (ΔpurDΔupp)
bearing pMPO90 plasmid, either uninduced (-) or induced by
salicylate for 4 h (+). Three μl of supernatant was loaded in
each track.
B. Analysis of conversion of 5-FC. Cytosine deaminase activity from
cell extracts of Salmonella MPO376 bearing pMPO54, pMPO1088
or pMPO90 plasmids, and MPO378 bearing pMPO90 either induced
by salicylate for 4 h, or not induced. Cytosine deaminase activity
was assayed as previously described (Nishiyama et al., 1985). Each
bar represents the average of three independent experiments ± SD.
Fig. 2. Effect of 5-FU produced on the bacterial growth. Serial dilutions (102 to 106) of cultures grown with or without salicylate were plated in
supplemented minimal E medium in the presence of 0.5 μM or 5 μM of 5-FC and incubated for 24 h at 37°C.
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rate of 5-FU. This clearly showed that 5-FU production
could be limited by the bacterium sensitivity to it.
This observation prompted us to obtain a Salmonella
mutant resistant to 5-FU, strain that could produce higher
amounts of this drug and for a longer time than the
isogenic sensitive strain using the same 5-FC dosage.
The mutant was constructed by deleting the upp gene
sequence, whose product is involved in 5-FU sensitivity
(Glaab et al., 2005), thus generating the strain MPO378
(ΔpurDΔupp). For the construction of upp mutant strain,
the ‘One Step Deletion’ approach was used to replace
target gene by the chloramphenicol resistance cassette
(Datsenko and Wanner, 2000). We transformed this strain
with the plasmid pMPO90 (CD7AUG) and performed the
same experiments to determine the amount of CD pro-
duced and the activity of whole-cell extracts of salicylate
induced cultures (Nishiyama et al., 1985). As shown in
Fig. 1A and B, CD production and activity were independ-
ent of the upp mutation, since the strain behaved as its
upp+ counterpart. Conversely, and as expected, the
mutant was resistant to the 5-FU produced when grown
on plates supplemented with 0.5 and 5 μM of 5-FC
(Fig. 2) despite the high CD activity achieved. These
results suggest that this strain and plasmid combination
may represent an improvement in bacterial cancer
therapy since it has the capacity of achieving a higher
5-FU concentration with a low 5-FC dosage, which, in
turns, would reduce the deleterious effect of this com-
pound in healthy eukaryotic cells.
A novel strategy to analyse the cytotoxic effect of
Salmonella-producing 5-FU in tumour cell cultures
Next, we decided to compare the consequences of 5-FU-
controlled production by the different plasmids and strains
obtained in this work in eukaryotic cell cultures. To deter-
mine the effects of 5-FU in eukaryotic cells, it is necessary
to analyse the evolution of cell cultures for 6 days after the
addition of this compound (Erbs et al., 2000; Bourbeau
et al., 2004). However, once Salmonella has infected the
eukaryotic cells, bacterial proliferation and expression of
certain bacterial proteins during the first hours of infection
induce host cell death within 18–24 h, hindering the
study of the effect of the 5-FU produced by Salmonella
in cell cultures (Kim et al., 1998; Paesold et al., 2002;
Mesa-Pereira et al., 2013). To analyse the effects of the
5-FU overproduced by Salmonella in cell cultures, we
generated a mutation in the producer strain to prevent
bacterial growth and protein production inside host cell.
It has been previously reported that attenuated purD
mutants are invasion proficient but unable to proliferate
once inside the eukaryotic cell. Nevertheless, the addition
of adenine to culture medium can temporally suppress
this deficiency (Leung and Finlay, 1991); thus, in a purD -
background, intracellular proliferation and CD overpro-
duction can be controlled by the presence of adenine and
salicylate respectively. This strategy has been recently
exploited in our laboratory to study the role of SpvB
Salmonella effector protein in the infection process
(Mesa-Pereira et al., 2013). In the present work, we have
used a similar experimental approach to study CD over-
production effects, and included a ΔpurD mutation in all
the strains used in this work. The strain MPO376 (ΔpurD)
bearing the empty vector, pMPO1088 (CDGUG) or
pMPO90 (CD7AUG) and the strain MPO378 (ΔpurDΔupp)
carrying pMPO90 were used to infect HeLa cells. After
invasion, adenine was added to infected cell cultures. and
1 h later, once infection was established, codA expression
was induced with salicylate. Five hours later, adenine
concentration was reduced 40-fold to avoid bacterial
proliferation, 50 μM of 5-FC was added and cells were
incubated for 6 days in the presence of salicylate and
5-FC. As a control, uninfected cell cultures followed the
same treatment but in the presence of 10 μM of 5-FU
(Erbs et al., 2000). The effects of codA overexpression
and 5-FU production were analysed by flow cytometry
and microscopy.
Figure 3A shows the cell cycle distribution of HeLa cell
cultures. As expected, most of the cells (67%) of the
control HeLa cell cultures in presence of 5-FC and
absence of 5-FU were in G0/G1 phase of the cell cycle.
Similarly, treatment with 5-FU produced the expected
effects on the cell cycle distribution (Pizzorno et al., 1995;
Takeda et al., 1999; Yoshikawa et al., 2001; De Angelis
et al., 2006): cells in G0/G1 phase were reduced down to
30%, while the dead cell population, represented as the
percentage of cells in sub-G1 phase of the cell cycle, and
cells arrested in S and G2/M phase were increased. Con-
versely, cell cycle of cells infected with the ΔpurD strain
bearing the empty vector were not affected even 6 days
after infection, which confirms that this mutant is unable to
induce cell death in the absence of adenine. Interestingly,
expression of CD by this proliferation deficient strain led to
a substantial alteration of the cell cycle distribution in a
way similar to 5-FU (increase in dead or arrested cells and
decrease in normal cells). Consistent with the above
experiments, infection with the ΔpurD strain bearing
pMPO1088 (CDGUG) had a slight but observable effect on
cell cycle distribution. However, the effect was much
higher when the infecting bacteria harboured pMPO90
(CD7AUG). In this case, there even was an increase in > 4N
cells indicative of aberrant endoreduplication. In addition,
the maximum effect on cell cycle distribution was
achieved when the strain bearing pMPO90 (CD7AUG) was
the 5-FU resistant strain ΔpurDΔupp (more cells in
sub-G1 than in G0/G1 phase), which was even more
pronounced than that induced with 10 μM of 5-FU in the
control culture. Accordingly, phase contrast microscopy
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showed much less proliferating HeLa cells when Salmo-
nella expressed CD from pMPO90 (CD7AUG), an effect that
was even more evident in these conditions than in 5-FU
treated cultures (Fig. 3B). Additionally, to test whether the
5-FU produced from these vectors and strains has similar
consequences on different tumour cell lines, we per-
formed the same analysis to determine the effects on
MCF-7 and HCT116 cell cycle distribution. As shown in
Fig. S1 (Supporting information), CD controlled expres-
sion produced similar effects on MCF-7 and HCT116 cell
cycle, thus showing they are not restricted to HeLa cells.
Taken together, these results demonstrate that upon
salicylate induction, Salmonella bearing the new codA
expressing construct produces more CD and converts
more 5-FU than the same strain transformed with the
former construct, which subsequently correlates with a
Fig. 3. In vitro sensitivity to 5-FU produced by Salmonella on infected HeLa cells.
A. Cell cycle distribution of HeLa cells infected with Salmonella MPO376 (ΔpurD) bearing pMPO54 (empty vector), pMPO1088 (CDGUG) or
pMPO90 (CD7AUG) and MPO378 (ΔpurDΔupp) bearing pMPO90, at multiplicity of infection 50:1. The cells were cultured in the presence of
50 μM of 5-FC and harvested at 6 days post-induction. Ten thousand events were analysed by flow cytometry for each sample. Graphics
represents the mean ± SD of three independent experiments. Non-infected HeLa cells treated with 50 μM of 5-FC or 10 μM of 5-FU were used
as controls. One-way analysis of variance and Tukey HSD post hoc tests were applied to test for significant differences. Data from the same
group marked with different alphabet are significantly different at P < 0.05.
B. Phase contrast microscopy of infected HeLa cells as well as uninfected control and HeLa cells treated with 5-FU are shown at day 6.
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higher cytotoxicity in HeLa, MCF-7 and HCT116 cells.
These high levels of 5-FU reached are also toxic to the
producer strain, although using an upp mutant to produce
CD circumvents this limitation. Finally, this experimental
approach combining the salicylate induced expression
system, and the purD mutant has proven to be effective to
analyse and compare the effect of different CD producing
strains on eukaryotic cell cycle. Thus, it can be a useful
tool to investigate the consequences on cell physiology of
any other cytotoxic protein produced by Salmonella,
evaluate its potential as anticancer therapy agent in cell
cultures and select the most appropriate combination of
strains and plasmids prior to their study in animal models.
Bystander activity of the 5-FU produced in cell cultures
Although Salmonella is able to invade tumour cells in
vitro, there is some controversy regarding bacterial locali-
zation in vivo and some data indicate that bacteria also
proliferates extracellulary in the necrotic region of solid
tumour (Westphal et al., 2008; Crull et al., 2011). There-
fore, the effectiveness of CD expressed by Salmonella in
cancer therapy depends on the bystander activity of the
produced drug. 5-fluorouracil has such bystander activity
since it passively diffuses from cell to cell. For that reason,
we compared the bystander effect on HeLa cell cultures
infected with the strain MPO376 (ΔpurD) bearing the
empty vector, pMPO90 (CD7AUG) or pMPO1088 (CDGUG)
and the strain MPO378 (ΔpurDΔupp) carrying pMPO90.
Cytosine deaminase expression was induced with salicy-
late as described above but, in this case, adenine was
always present in the cultures at normal concentration.
Forty hours after infection, supernatants of the different
cultures were transferred to uninfected HeLa cells, and
cell cycle distribution was analysed by flow cytometry 6
days later. Since supernatant transfer to fresh cultures
resulted in a fivefold dilution, we used uninfected cultures
treated with either 10 μM or 50 μM 5-FU as control,
so they were also diluted to about 2 μM and 10 μM
respectively.
The experiments, summarized in Fig. 4, revealed a
bystander effect of the three CD-expressing Salmonella
when compared with the strain carrying the empty vector.
An increase in the sub-G1 population can be observed
with these three strains. Although there is little difference
between the effects detected with the ΔpurD strain carry-
ing either pMPO90 (CD7AUG) or pMPO1088 (CDGUG), the
higher effect was again achieved with the ΔpurDΔupp
strain carrying pMPO90 plasmid. In fact, the conse-
quences on cell cycle distribution caused by this combi-
nation of strain and plasmid were even greater than those
generated in the control cultures.
Current gene delivery systems have low efficiency tar-
geting tumour tissues and can transduce only a small
percentage of cells within a tumour. In consequence, the
clinical use of cancer gene therapy is limited. Gene
therapy approaches to express CD by transformed
tumour cells could surpass this limitation due to the
bystander effect of the CD/5-FU system. Given that CD
has a cytosolic location, a possible limitation of this
approach is that CD-expressing cells are killed before
cytotoxic concentrations of extracellular 5-FU are
Fig. 4. Bystander effect: Cytotoxicity of supernatants from infected HeLa cells treated with 5-FC. HeLa cells were infected at multiplicity of
infection 50:1 and were grown in presence of 5-FC 250 μM in medium supplemented with adenine. Media were collected 40 h later, diluted
1:5 and added to uninfected HeLa cells. Effect of 5-FU produced was determined at day 6 by cell cycle analysis. Graphics represents
mean ± SD of three independent experiments. Non-infected HeLa cells treated with 50 μM of 5-FC, 10 μM and 50 μM of 5-FU were used as
controls. One-way analysis of variance and Tukey HSD post hoc tests were applied to test for significant differences. Data from the same
group marked with different alphabet are significantly different at P < 0.05.
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reached, limiting in this way the bystander effect and,
therefore, the anti-tumour efficiency (Lawrence et al.,
1998). Better results would probably be obtained by
expressing a secreted form of CD (Rehemtulla et al.,
2004) or, specially, using Salmonella as a delivery vector,
because it selectively targets tumours and preferentially
colonizes extracellular compartments (Pawelek et al.,
1997; Agorio et al., 2007; Loessner et al., 2007; Leschner
and Weiss, 2010; Crull et al., 2011). Bacterial production
of CD also has limitations since Salmonella is also sensi-
tive to the high concentrations of 5-FU achieved.
However, the upp- 5-FU resistance mutation in Salmonella
would make the bacterial strain more competent in cancer
therapy as it circumvents the suicide of the drug ‘factory’
and increases the bystander effect. The results of this
work show that a Salmonella strain that combines high
production levels of CD such as those achieved with
pMPO90 with resistance to 5-FU due to the upp- mutation
is a better candidate to be used to intra-tumourally deliv-
ered 5-FU in cancer treatment.
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Supporting information
Additional Supporting Information may be found in the
online version of this article at the publisher’s web-site:
Fig. S1. In vitro sensitivity to 5-FU produced by Salmonella
on infected MCF-7 and HCT116 cells. A cell cycle distribution
of MCF-7 (A) or HCT116 (B) cells infected with Salmonella
MPO376 (ΔpurD) bearing pMPO54 (empty vector),
pMPO1088 (CDGUG) or pMPO90 (CD7AUG) and MPO378
(ΔpurDΔupp) bearing pMPO90, at multiplicity of infection
50:1. The cells were cultured in the presence of 50 μM of
5-FC and harvested at 6 days post-induction. 10 000 events
were analysed by flow cytometry for each sample. Graphics
represents the mean ± SD of three independent experiments.
Non-infected cells treated with 50 μM of 5-FC or 10 μM of
5-FU were used as controls. One-way ANOVA and Tukey
HSD post hoc tests were applied to test for significant differ-
ences. Data from the same group marked with different
alphabet are significantly different at P < 0.05.
Table S1. Bacterial strains and plasmids used in or con-
structed for this study.
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